#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Medical Center - University Of Freiburg

Verifiedinfo

Germany Hugstetter Strasse 55, Stuehlinger, 79106 Freiburg Im Breisgau, Germany

200 trials recruiting
Arteriosclerosis · Acute myeloid leukaemia · Sjogren's syndrome
Adults and children

About Specializations

Medical Center - University Of Freiburg in Freiburg Im Breisgau, Germany specialises in clinical trials of conditions such as Arteriosclerosis, Acute myeloid leukaemia, Sjogren's syndrome, Plasma cell myeloma, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms

The Klinik für Strahlenheilkunde at the Medical Center – University Of Freiburg conducts cutting‑edge research in radiation oncology, concentrating on aggressive brain tumors such as glioblastoma and astrocytoma.

Evaluation of a novel vaccine for surgically resected glioblastoma
Investigation of therapeutic strategies for astrocytoma with unmethylated molecular signature
Assessment of safety and optimal dosing in post‑surgical patients

The site is located in Freiburg Im Breisgau, Germany, supports 7 active clinical studies and involves a team of over 125 investigators dedicated to improving outcomes for patients with malignant brain tumors.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Hugstetter Strasse 55, Stuehlinger79106 Freiburg Im BreisgauGermany

Open in maps ↗

Recruiting now: 200 trials
Conditions studied: 233
Partner status: Verified

More sites in Freiburg Im Breisgau Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

507 clinical trials

Bladder transitional cell carcinoma+1

Recruiting

Registered drug

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Eli Lilly & Co.

Contact Research Centre

Cardiac failure+1

Recruiting

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Eczema nummular

Recruiting

Registered drug

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Lebrikizumab
Sponsor:Almirall S.A.

Contact Research Centre

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Registered drug

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Empasiprubart
Sponsor:Argenx

Contact Research Centre

Small cell lung cancer+2

Recruiting

Registered drugNo placebo

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:BioNTech SE

Contact Research Centre

Palmoplantar pustulosis

Recruiting

Registered drug

A Study Testing How Well Bimekizumab Works and How Safe It Is for Adults with Palmoplantar Pustulosis

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Bimekizumab
Sponsor:UCB Biopharma

Contact Research Centre

Cachexia

Recruiting

Investigational

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:VISUGROMAB
Sponsor:CatalYm GmbH

Contact Research Centre

Dermatitis atopic

Recruiting

Investigational

Long-term safety and effectiveness study of APG777 injection in patients with moderate-to-severe atopic dermatitis who previously received APG777 treatment

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Apg777
Sponsor:Apogee Therapeutics Inc.

Contact Research Centre

Cardiovascular disorder+2

Recruiting

Registered drug

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Bi 690517
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Arteriosclerosis

Recruiting

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:AstraZeneca AB

Contact Research Centre

Bronchiectasis

Recruiting

Investigational

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bi 1291583
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Arteriosclerosis

Recruiting

Investigational

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.